Trial Success Signals Hope for Combined COVID/Flu Protection

Trial Success Signals Hope for Combined COVID/Flu Protection
Trial Success Signals Hope for Combined COVID/Flu Protection. Credit | Iparraguirre Recio

United States: Moderna, the maker of this experimental vaccine, recently revealed that trials involving older persons are yielding encouraging results. This vaccine could provide one-stop prophylaxis for both COVID-19 and influenza.

Higher Immune Response

“Has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial,” Moderna said in a statement about the injection, which is now known as mRNA-1083.

The phase 3 trial is just one more step toward the dual-purpose shot’s clearance; it won’t be approved in time for the flu season this year.

Potential Impact on Healthcare

Nevertheless, “combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses,” Stéphane Bancel, CEO of Moderna, said in the statement.

According to the originator the new vaccine contains “ components of mRNA-1010, Moderna’s vaccine patients for several influenza, and mRNA-1283, Moderna’s next generation COVID-19 vaccine candidate.

Trial Details

And this particular trial involving almost more than 4,000 adults ages 65 or older, the mRNA-1083 vaccine affected the immune responses to three influenza variants as well as to the SARS-CoV-2 virus which cause the COVID that equaled those of vaccines who are already approved against either flu or COVID. The three influenza variants are H1N1, H3N2 and B/ Victoria.

Though the same results were also seen in another group of about 4,000 people between 50 and 64 years of age, Modena said.

Blinded Study

The trial was “Blinded”  which means neither the patients nor the people  conducting the trial knew who got vaccines

Pending Review

Although Moderna stated that company intends to submit the study results for publication and for FDA review, the new findings have not yet undergone peer review.

Public Reception

In reality, the question is whether Americans who are tired of vaccinations will use the dual-purpose vaccine if it is made available, according to Sue Peschin, president and CEO of the nonprofit Alliance for Aging Research.

In an interview with CNN, she pointed out that fewer Americans are receiving any kind of vaccination.

Vaccination Rates

For example, a presentation made to the FDA last week revealed that only 25% of eligible Americans have received the most recent COVID-19 vaccination. There was a small increase in the number of people who received the flu vaccination last year; according to the Centers for Disease Control and Prevention, over half adults got on last season.

We want to see that increase, and if combining the vaccines is one way to do that, then it’s better for everyone because it helps protect everyone in the community, according to Peschin. “If the FDA finds the combination vaccines to be safe and effective, we would love to see them go on sale.”